Document Detail

Langerhans cell histiocytosis in neonates.
MedLine Citation:
PMID:  15770639     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: To study the incidence, clinical patterns, course, and outcome of neonatal Langerhans cell histiocytosis (LCH). PROCEDURE: Retrospective analysis of the data of the Austrian/German/Swiss/Netherlands LCH Study Group. The incidence of neonatal LCH was estimated with the data from the population-based German Childhood Cancer Registry. RESULTS: The estimated incidence of neonatal LCH (LCH diagnosed within 28 days after birth) in the population-based registry was 1-2/1,000,000. In 61/1,069 trial patients (6%), the first disease manifestations were observed in the neonatal period. However, in only 20 of them, the diagnosis was established within this period. There was a preponderance of multisystem (MS)-LCH 36/61 (59%). Cutaneous changes were the most common initial manifestation in both, single-system (SS)-LCH (92%), and MS-LCH (86%). In 72% of the MS-LCH patients, risk organs (ROs) were involved at diagnosis as well. The probability of survival at 5 years was 94% in SS-LCH and 57% in MS-LCH, which is significantly lower than in older age groups. CONCLUSIONS: In contrast to the available literature, neonatal LCH is characterized by a clear predominance of MS-LCH. Cutaneous changes are the most common initial manifestation in neonates with both SS-LCH and MS-LCH. Prompt evaluation of disease extent upon diagnosis is mandatory for risk-adapted treatment. The disease course is unpredictable upon diagnosis. Close monitoring for disease progression is mandatory if isolated cutaneous LCH is managed by the "wait and see" approach. Neonates with MS-LCH, especially those with RO involvement at diagnosis, have less favorable prognosis compared to infants and older children, and need systemic therapy.
M Minkov; H Prosch; M Steiner; N Grois; U Pötschger; P Kaatsch; G Janka-Schaub; H Gadner
Related Documents :
15770639 - Langerhans cell histiocytosis in neonates.
7746239 - Assessment and management of opioid withdrawal in ill neonates.
19026339 - Technical aspects of starting a neonatal cooling program.
19940829 - Long-term use of neonatal helmet-cpap: a case report.
8728259 - Peritoneal dialysis prescription for neonates.
1811919 - Developmental electrophysiologic effects of propafenone and 5-hydroxypropafenone on the...
15482799 - Sensitivity to linear-speed-gradient of radial expansion flow in infancy.
16027579 - May the best friend be an enemy if not recognized early: hypernatremic dehydration due ...
21655749 - Predictive score for clinical complications during intra-hospital transports of infants...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Pediatric blood & cancer     Volume:  45     ISSN:  1545-5009     ISO Abbreviation:  Pediatr Blood Cancer     Publication Date:  2005 Nov 
Date Detail:
Created Date:  2005-09-19     Completed Date:  2005-12-28     Revised Date:  2009-01-12    
Medline Journal Info:
Nlm Unique ID:  101186624     Medline TA:  Pediatr Blood Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  802-7     Citation Subset:  IM    
Copyright Information:
(c) 2005 Wiley-Liss, Inc.
St. Anna Children's Hospital, Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Disease Progression
Histiocytosis, Langerhans-Cell / diagnosis,  epidemiology*,  mortality,  therapy
Infant, Newborn
Retrospective Studies
Risk Assessment
Skin Diseases
Survival Analysis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Analysis of telomerase activity and RNA expression in a patient with acute promyelocytic leukemia tr...
Next Document:  Successful treatment of doxorubicin and cisplatin resistant hepatoblastoma in a child with Beckwith-...